GlassScriptPhysician profile
Kayla Penny
NPI 1982344867
$2,498.07
in general payments reported to CMS, 2019-2025
15 companies · $870 in 2025
The $870 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $421 · 2024: $1,207 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.92 | 2023-2025 | Rinvoq, Skyrizi, Dalvance |
| Genzyme Corporation | $287.70 | 2023-2024 | |
| Ucb, INC. | $258.80 | 2023-2024 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $230.09 | 2024 | Dupixent |
| Janssen Biotech, INC. | $135.76 | 2024-2025 | Tremfya |
| Incyte Corporation | $126.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $120.81 | 2024-2025 | |
| Dermavant Sciences, INC. | $72.81 | 2023-2024 | Vtama |
| Pfizer INC. | $51.68 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $36.96 | 2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.76 | 2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $24.91 | 2023 | Sotyktu |
| Amgen INC. | $24.37 | 2025 | Otezla |
| Lilly USA, LLC | $21.25 | 2024 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $14.91 | 2023 | Oracea, Epsolay, Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Penny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.